P1.16-26 Safety of SABR (Stereotactic Ablative Body Radiotherapy) for Central Non-Small Cell Lung Cancers (cNSCLC) With 50 Gray in 5 Fractions (50Gy/5f)

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.995
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

MTE24.02 Small Lung Tumours: High Risk Lesions and Contraindications to Stereotactic Ablative Body Radiotherapy (SABR)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Stereotactic Body Radiotherapy for Large (> 5 Cm) Non–Small-Cell Lung Cancer

Clinical Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2017English

Imaging Follow-Up After Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors

Journal of Radiation Oncology
OncologyRadiologyNuclear MedicineImaging
2012English

P1.16-23 Long-Term Survival Analysis of Surgery in Potential Stereotactic Ablative Radiotherapy Candidates of Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Population-Based Phase II Trial of Stereotactic Ablative Radiotherapy (SABR) for Up to 5 Oligometastases: SABR-5

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Standardization of Stereotactic Body Radiotherapy for Non-Small Cell Lung Cancer

Japanese Journal of Lung Cancer
OncologyRespiratory MedicinePulmonary
2015English

MS20.02 the Future of Stereotactic Ablative Radiotherapy (SABR)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.16-29 Accelerated Hypofractionated Radiotherapy for Central Lung Tumors Unsuitable for Stereotactic Body Radiotherapy or Concurrent CRT

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Feasibility of Stereotactic Body Radiotherapy for Locally-Advanced Non-Small Cell Lung Cancer

Clinical and Translational Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy